ABBV vs JPM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and JPMorgan Chase & Co. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
JPMorgan Chase & Co. · Financial Services
$309.87
-6.4% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
JPM trades at a lower forward P/E
(14.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JPM |
| Current Price |
$208.05 |
$309.87 |
| Fair Value Estimate |
$217.50 |
$290.00 |
| Upside to Fair Value |
+4.5%
|
-6.4%
|
| Market Cap |
$367.9B |
$835.7B |
| Forward P/E |
14.9x
|
14.3x
|
| EV / EBITDA |
16.7x
|
17.6x
|
| Price / Sales |
6.1x
|
3.0x
|
| Price / FCF |
20.9x
|
—
|
| Revenue Growth YoY |
+8.6%
|
+3.3%
|
| Gross Margin |
83.7%
|
59.99%
|
| Operating Margin |
34.7%
|
25.9%
|
| Return on Equity |
-129.24%
|
15.95%
|
| Dividend Yield |
3.2% |
1.9% |
| FCF Yield |
4.78%
|
—
|
| Analyst Consensus |
Buy
|
Overweight
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
JPMorgan Chase is the largest U.S. bank by assets ($4.4T) and the most diversified financial services franchise globally, operating across consumer banking, investment banking, commercial banking, and asset management. Under Jamie Dimon's two-decade leadership, the firm has consistently gained market share, delivered sector-leading ROE of 16%, and invested aggressively in technology ($17B+ annual…
Accumulation Zones
| Metric |
ABBV |
JPM |
| Zone Low |
$163.13 |
$220.00 |
| Zone High |
$184.88 |
$250.00 |
| In Buy Zone? |
No
|
No
|